Session

Sophisticated approaches to advanced RCC

Poster Session 69

  • Location:
    Room Copenhagen, North Hall (Level 1)
  • Chairs:
     J.I. Martínez Salamanca, Majadahonda (ES)
     V. Matveev, Moscow (RU)
     M.C. Mir Maresma, Cleveland (US)
  • Aims and objectives of this session

    To discuss different surgical aspects of nephrectomy for advanced RCC.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
910
Renal tumor management in Scandinavia: A multi-institutional survey

By: Nisen H.1, Jarvinen P.1, Lund L.2, Ljungberg B3, Kromann-Andersen B.4, Gudmundsson E.5, Sundqvist P.6, Fovaeus M.7, Nilsen F.8, Beisland C.9

Institutes: 1HUCH Helsinki University Central Hospital, Dept. of Urology, Helsinki, Finland, 2Odense University Hospital, Dept. of Urology, Odense, Denmark, 3Umeå University, Dept. of Surgical and Perioperative Sciences, Umeå, Sweden, 4Herlev University Hospital, Dept. of Urology, Copenhagen, Denmark, 5Landspitali, Dept. of Urology, Reykjavik, Iceland, 6Örebro University Hospital, Dept. of Urology, Örebro, Sweden, 7Sahlgrenska University Hospital, Dept. of Urology, Gothenburg, Sweden, 8Akershus University Hospital, Dept. of Urology, Oslo, Norway, 9Haukelan University Hospital, Dept. of Urology, Bergen, Norway

911
Multicenter analysis of oncologic and renal functional outcomes of radical and partial nephrectomy in stage II renal cell carcinoma

By: Hamilton Z.1, Correa A.2, Larcher A.4, Khene Z.3, Fero K.1, Han D.1, Bloch A.1, Field C.1, Peyronnet B.3, Capitanio U.4, Montorsi F.4, Bensalah K.3, Uzzo R.2, Derweesh I.1

Institutes: 1Moores Cancer Center, Dept. of Urology, La Jolla, United States of America, 2Fox Chase Cancer Center, Dept. of Urology, Philadelphia, United States of America, 3University of Rennes, Dept. of Urology, Rennes, France, 4San Raffaele Scientific Institute, Dept. of Urology, Milan, Italy

912
Partial versus radical nephrectomy in patients with renal cell carcinoma and renal or caval thrombus: Oncological and functional outcomes from an individual matched cohort analysis

By: Marra G.1, Gontero P.1, Brattoli M.1, Filippini C.2, Linares Espinos E.3, Capitanio U.4, Montorsi F.4, Daneshmand S.6, Huang W.C.7, Martínez-Salamanca J.I.8, McKiernan J.M.9, Scherr D.S.10, Zigeuner R.11, Libertino J.A.5

Institutes: 1San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, 2San GIovanni Battista Hospital, Dept. of Urology, Turin, Italy, 3Hospital Universitario Puerta De Hierro-Madrid, Dept. of Urology, Madrid, Spain, 4San Raffaele Hospital, Dept. of Urology, Milan, Italy, 5Lahey Clinic, Dept. of Urology, Burlington, United States of America, 6USC/Norris Comprehensive Cancer Center, Dept. of Urology, Los Angeles, United States of America, 7University School of Medicine, Dept. of Urology, New York, United States of America, 8Hospital Universitario Puerta de Hierro-Majadahonda, Universidad Autónoma de Madrid, Dept. of Urology, Madrid, Spain, 9Columbia University College of Physicians and Surgeons, Dept. of Urology, New York, United States of America, 10Weill Cornell Medical Center, Dept. of Urology, New York, United States of America, 11Medical University of Graz, Dept. of Urology, Graz, Austria

913
Comparison of different surgical approaches for the management of renal cell carcinoma invading the renal vein

By: Hanna N., Ingham M., Seisen T., Chang S.

Institutes: Brigham and Women’s Hospital, Dept. of Urology, Boston, United States of America

914
Robot assisted radical nephrectomy and inferior vena cava thrombectomy: Surgical technique, perioperative and oncologic outcomes

By: Simone G.1, Hatcher D.2, Ferriero M.1, Minisola F.1, Misuraca L.1, Tuderti G.1, Guaglianone S.1, De Castro Abreu A.L.2, Aron M.2, Desai M.2, Gill I.S.2, Gallucci M.1

Institutes: 1Regina Elena National Cancer Institute, Dept. of Urology, Rome, Italy, 2Keck School of Medicine, University of Southern California, Institute of Urology, Los Angeles, United States of America

915
Robotic versus open inferior Vena cava (IVC) tumor thrombectomy: The initial comparison

By: Chopra S., Loh-Doyle J., Cai J., Daneshman S., Djaladat H., Desai M., Gallucci M., Gill I.S.

Institutes: Usc Institute of Urology, Dept. of Urology, Los Angeles, United States of America

916
Comparison between laparoendoscopic single site nephrectomy and conventional laparoscopic nephrectomy: A randomized control single institution experience

By: Eltemamy M., Abdel Hakim M., El-Feel A., Abdel Wahab M., Abdallah A., Elshafei A., Omar A.-R.

Institutes: Cairo University, Dept. of Urology, Cairo, Egypt

917
Impact of intraoperative blood transfusions on survival after surgery for renal cell carcinoma

By: La Croce G., Muttin F., Moschini M., Larcher A., Dell’Oglio P., Nini A., Ripa F., Cianflone F., Di Trapani E., Carenzi C., Dehò F., Montorsi F., Bertini R., Capitanio U.

Institutes: IRCCS Ospedale San Raffaele, Urological Research Institute, Unit of Urology, Division of Oncology, Milan, Italy

918
The efficacy of neoadjuvant targeted therapy in treatment of localized RCC

By: Voylenko O., Vitruk I., Stakhovskyi O., Kononenko O., Pikul M., Stakhovsky E.

Institutes: National Cancer Institute, Dept. of Plastic and Reconstructive Oncological Urology, Kiev, Ukraine

919
Clinical benefit of presurgical axitinib therapy in renal cell carcinoma patients with thrombus extending to inferior vena cava

By: Tanaka Y., Hashimoto Y., Hatakeyama S., Hosogoe S., Noro D., Oikawa M., Tanaka T., Narita T., Hagiwara K., Tobisawa Y., Yamamoto H., Yoneyama T., Yoneyama T., Koie T., Ohyama C.

Institutes: Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan

920
Phase II study of axitinib for downstaging cT2a to cT1 renal tumors for allowing partial nephrectomy (AXIPAN)

By: Lebacle C.1, Bernhard J.C.2, Bensalah K.3, Baumert H.4, Lang H.5, Jacqmin D.5, Duclos B.6, Ravaud A.7, Laguerre B.8, Albiges L.9, Arnoux A.10, Escudier B.9, Patard J.J.1

Institutes: 1Bicêtre University Hospital, Dept. of Urology, Le Kremlin-Bicêtre, France, 2Pellegrin Hospital, Dept. of Urology, Bordeaux, France, 3Pontchaillou University Hospital, Dept. of Urology, Rennes, France, 4Saint-Joseph Hospital, Dept. of Urology, Paris, France, 5Hôpitaux Universitaires De Strasbourg, Nouvel Hôpital Civil, Dept. of Urology, Strasbourg, France, 6Hôpitaux Universitaires De Strasbourg, Hôpital Hautepierre, Dept. of Oncology, Strasbourg, France, 7Saint-André Hospital, University Hospital, CHU Bordeaux, Dept. of Medical Oncology, Bordeaux, France, 8Eugène Marquis Center, Dept. of Oncology, Rennes, France, 9Gustave Roussy Université Paris-Saclay, Dept. of Medicine, Villejuif, France, 10Bicetre University Hospital, Dept. of Statistics, Le Kremlin-Bicêtre, France

921
Meta-analysis of upfront VEGF targeted therapy prior to nephrectomy in metastatic clear cell renal cancer

By: Szabados B.1, Gomez De Liano Lista A.1, Wimalasingham A.1, De Bruijn R.2, Haanen J.3, Blank C.3, Hall P.4, Staehler M.6, Chowdhury S.5, Hopkins T.4, Powles T.4, Bex A.2

Institutes: 1Barts Health Nhs Trust St Bartholomew’s Hospital, Dept. of Oncology, London, United Kingdom, 2The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, 3The Netherlands Cancer Institute, Dept. of Oncology, Amsterdam, The Netherlands, 4Barts Health NHS Trust St Bartholomew’s Hospital, Dept. of Oncology, London, United Kingdom, 5Guy’s, King’s and St Thomas’ Hospitals, Dept. of Oncology, London, United Kingdom, 6University Hospital Munich-Grosshadern, Dept. of Urology, Munich, Germany

922
S-TRAC adjuvant sunitinib phase 3 trial in patients with high risk renal cell carcinoma: Subgroups analyses by risk factors

By: Staehler M.1, Patard J-J.2, Pantuck A.3, Ravaud A.4, Motzer R.5, Pandha H.6, George D.7, Chang Y-H.8, Escudier B.9, Donskov F.10, Magheli A.11, Carteni G.12, Laguerre B.13, Tomczak P.14, Breza J.15, Gerletti P.16, Lechuga M.16, Lin X.17, Casey M.18, Patel A.19

Institutes: 1University Hospital of Munich, Dept. of Urology, Munich, Germany, 2Bicêtre Hospital, Paris-Saclay University, Dept. of Urology, Le Kremlin Bicêtre, France, 3Ronald Reagan UCLA Medical Center, Dept. of Urology, Los Angeles, Ca, United States of America, 4Bordeaux University Hospital, Dept. of Medical Oncology, Bordeaux, France, 5Memorial Sloan Kettering Cancer Center, Dept. of Oncology, New York, United States of America, 6University of Surrey, Dept. of Clinical and Experimental Medicine, Surrey, United Kingdom, 7Duke Cancer Center, Dept. of Oncology, Durham, United States of America, 8Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, 9Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, France, 10Aarhus University Hospital, Dept. of Oncology, Aarhus, Denmark, 11Charité Universitaetsmedizin Berlin, Dept. of Urology, Berlin, Germany, 12Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli,, Dept. of Oncology and Urology, Naples, Italy, 13Centre Eugene Marquis, Dept. of Medical Oncology, Rennes, France, 14Klinika Onkologii Oddzial Chemioterapii, Dept. of Oncology, Poznan, Poland, 15Slovak Medical University In Bratislava, Dept. of Urology, Bratislava, Slovakia, 16Pfizer S.r.L, Dept. of Oncology, Milan, Italy, 17Pfizer Inc, Dept. of Oncology, La Jolla, United States of America, 18Pfizer Inc, Dept. of Oncology, New York, United States of America, 19Spire Roding Hospital, Dept. of Urology, London, United Kingdom

Summary
 M.C. Mir Maresma, Cleveland (US)